

Table 2: Response rates, response duration, overall survival and side effects in the largest studies on single-agent or multi-agent therapy for advanced CTCLs*

Treatment	Pts (n.)	Histologic types of lymphomas and stage	CR/OR (%)	Median duration of response (mo.s)	OS (mo.s or %)	Adverse effects and grading	Ref.
BPCE	20	MF Stage III 15% Stage IV 85%	85/90	8 for CR	50% at 24 mo.s 30% at 48 mo.s	Hemorrhagic cystitis 25% pulmonary fibrosis 25% mild retinoid-related AEs	11
Peg-Doxo	34	MF 30 Stage IIB → IVA 63% Folliculotropic MF 2/30 PTCL-U 2; ALCL 1; SS 1	44/88	EFS 12 DFS 13.3	17.8 mo.s	Toxicity all grades 41% grade III-IV 18% grade II/III PPE 3% / 6%	7
Peg-Doxo	19	MF 13 Stage IIB → IV 69% Folliculotropic MF 3/13 MF transf. in ALCL 3/13 PTCL-U 3; SS 3	42/84	EFS 18 PFS 19	34 mo.s 44% at 46 mo.s	Toxicity all grades 26% grade III-IV 11% grade I PPE 5%	Our study
CAVE ± TSEBI**	52	MF Stage IIB → IVB 69%	38/90	DFS 13.7 no differences between the two arms	93 mo.s no differences between the two arms	Considerable toxicity: hospitalization for fever 23 % CHF 10%	12
VICOP-B	25	MF 19 Stage IIB → IVB Pleomorphic 4; SS 2	36/80	7.3 for OR; EFS 22; PFS 6.8; 8.7 for OR in MF no responses in SS patients	NR	Alopecia 75%; nausea 48% peripheral neuropathy 36% grade IV neutropenia 32%	13
ALEMTUZUMAB	22	MF 15 Stage IIB → IVB 95% SS 7	32/55	TTF 12 for CR	NR	CMV 18%; gr. IV neutropenia 18% grade IV thrombocytopenia 5% HSV 4%; Aspergillosis 4% Mycobacteria pneumonia 4%	14
EPOCH	15	MF 5; ALCL 4 (1 HTLV1+ blastic transf.) Stage IIB → IVB SS 6	27/80	PFS 8	13.5 mo.s	Gr. III/IV myelosuppression 61%, neurotoxicity/cardiac toxicity 6%, Pneumocystis c. pneumonia 6%, HSV infection 13%	15
CVP	16	MF 12 Stage IIB → IVB SS 4	25/50	12 for OR	48 mo.s	Nausea/vomiting 62% gr. III-IV myelosuppression 44%	16
CHOP/CHOP like	35	MF 17, T-cell immunoblastic 3, PTCL-U 2 ; SS 13	23/40	5.7 for OR	19 mo.s	Alopecia 80%, nausea/vomiting 30%, gr. III-IV neutropenia 30%, neurotoxicity 20%	17
Gemcitabine	32°	MF 26 stage IIB → IIIA; PTCL-U 5; SS 1	22/75	PFS 10	19 mo.s	Grade III-IV neutropenia 16%, gr. III-IV thrombocytopenia 12%, gr. IV hepatic toxicity 3%	18